Literature DB >> 16764679

D4 Dopamine receptor genes of zebrafish and effects of the antipsychotic clozapine on larval swimming behaviour.

W Boehmler1, T Carr, C Thisse, B Thisse, V A Canfield, R Levenson.   

Abstract

Zebrafish, a model developmental genetic organism, is being increasingly used in behavioural studies. We have initiated studies designed to evaluate the response of zebrafish to antipsychotic drugs. This study focuses on characterization of zebrafish D4 dopamine receptors (D4Rs) and the response of larval zebrafish to the atypical antipsychotic clozapine. The D4R is of interest because of its high affinity for clozapine, while interest in clozapine stems from its effectiveness in reducing symptoms in acutely psychotic, treatment-resistant schizophrenic patients. By mining the zebrafish genomic database, we identified three distinct D4R genes, drd4a, drd4b and drd4c, and generated full-length open reading frames encoding each of the three D4Rs by reverse transcription-polymerase chain reaction. Gene mapping studies showed that each D4R gene mapped to a distinct chromosomal location in the zebrafish genome, and each gene exhibited a unique expression profile during embryogenesis. When administered to larval zebrafish, clozapine produced a rapid and profound effect on locomotor activity. The effect of clozapine was dose-dependent, resulted in hypoactivity and was prevented by the D4-selective agonist ABT-724. Our data suggest that the inhibitory effect of clozapine on the locomotor activity of larval zebrafish may be mediated through D4Rs.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 16764679     DOI: 10.1111/j.1601-183X.2006.00243.x

Source DB:  PubMed          Journal:  Genes Brain Behav        ISSN: 1601-183X            Impact factor:   3.449


  37 in total

Review 1.  Evolutionary genomics of animal personality.

Authors:  Kees van Oers; Jakob C Mueller
Journal:  Philos Trans R Soc Lond B Biol Sci       Date:  2010-12-27       Impact factor: 6.237

2.  Strain dependent gene expression and neurochemical levels in the brain of zebrafish: focus on a few alcohol related targets.

Authors:  Y Pan; D Chatterjee; R Gerlai
Journal:  Physiol Behav       Date:  2012-02-01

3.  Kinetics and pharmacology of the D1- and D2-like dopamine receptors in Japanese quail brain.

Authors:  Lubica Kubíková; Pavel Výboh; Lubor Kostál
Journal:  Cell Mol Neurobiol       Date:  2009-03-28       Impact factor: 5.046

4.  Acute administration of dopaminergic drugs has differential effects on locomotion in larval zebrafish.

Authors:  T D Irons; P E Kelly; D L Hunter; R C Macphail; S Padilla
Journal:  Pharmacol Biochem Behav       Date:  2012-12-28       Impact factor: 3.533

5.  Differential effects of dopamine D1 and D 2/3 receptor antagonism on motor responses.

Authors:  Steven Tran; Magda Nowicki; Arrujyan Muraleetharan; Robert Gerlai
Journal:  Psychopharmacology (Berl)       Date:  2014-08-20       Impact factor: 4.530

6.  Behavioral screening of the LOPAC1280 library in zebrafish embryos.

Authors:  Sara M Vliet; Trina C Ho; David C Volz
Journal:  Toxicol Appl Pharmacol       Date:  2017-06-13       Impact factor: 4.219

Review 7.  Zebrafish as an emerging model for studying complex brain disorders.

Authors:  Allan V Kalueff; Adam Michael Stewart; Robert Gerlai
Journal:  Trends Pharmacol Sci       Date:  2014-01-09       Impact factor: 14.819

8.  Behavioural changes controlled by catecholaminergic systems explain recurrent loss of pigmentation in cavefish.

Authors:  Helena Bilandžija; Lindsey Abraham; Li Ma; Kenneth J Renner; William R Jeffery
Journal:  Proc Biol Sci       Date:  2018-05-16       Impact factor: 5.349

Review 9.  Dopaminergic system in birdsong learning and maintenance.

Authors:  Lubica Kubikova; Lubor Kostál
Journal:  J Chem Neuroanat       Date:  2009-11-10       Impact factor: 3.052

10.  Alcohol-induced behavioral changes in zebrafish: The role of dopamine D2-like receptors.

Authors:  Steven Tran; Amanda Facciol; Robert Gerlai
Journal:  Psychopharmacology (Berl)       Date:  2016-03-09       Impact factor: 4.530

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.